About MiNA Therapeutics
MiNA Therapeutics is a company based in London (United Kingdom) founded in 2008 by Pal Saetrom, Nagy Habib, and John Rossi. MiNA Therapeutics has raised $458.78 million across 8 funding rounds from investors including Lilly, Boehringer Ingelheim and Nxera Pharma. The company has 37 employees as of December 31, 2022. MiNA Therapeutics offers products and services including RNAa Therapeutics and Pipeline Programs. MiNA Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter London, United Kingdom
- Employees 37 as on 31 Dec, 2022
- Founders Pal Saetrom, Nagy Habib, John Rossi
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mina Therapeutics Limited
- Date of Incorporation 07 Mar, 2008
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
$23.07 M (USD)839as on Dec 31, 2021
-
Net Profit
-$26.96 M (USD)-4681as on Dec 31, 2022
-
EBITDA
-$31.28 M (USD)-5520as on Dec 31, 2022
-
Total Equity Funding
$458.78 M (USD)
in 8 rounds
-
Latest Funding Round
$15 M (USD), Series A
Jul 06, 2021
-
Investors
Lilly
& 3 more
-
Employee Count
37
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MiNA Therapeutics
MiNA Therapeutics offers a comprehensive portfolio of products and services, including RNAa Therapeutics and Pipeline Programs.
Medicines that activate genes to restore cellular functions for disease treatment.
Advancing medicines for genetic diseases through research and trials.
People of MiNA Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of MiNA Therapeutics
MiNA Therapeutics has successfully raised a total of $458.78M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $15 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MiNA Therapeutics
MiNA Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Boehringer Ingelheim and Nxera Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in healthcare are focused on by aMoon.
|
Locked | Locked | Locked | |
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Locked | Locked | Locked | |
|
Generic drugs and clinical research services are provided globally.
|
Locked | Locked | Locked |
Investor details for MiNA Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MiNA Therapeutics
Investment portfolio details for MiNA Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MiNA Therapeutics
Detailed financials for MiNA Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mina Therapeutics Comparisons
Peer comparison for MiNA Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MiNA Therapeutics
MiNA Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of MiNA Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mina Therapeutics
Complete news archive for MiNA Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MiNA Therapeutics
MiNA Therapeutics was founded in 2008 and raised its 1st funding round 6 years after it was founded.
MiNA Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Robert Sebastian Habib is the current CEO of MiNA Therapeutics.
MiNA Therapeutics is a funded company, having raised a total of $458.78M across 8 funding rounds to date.
As of Dec 31, 2022, the latest employee count at MiNA Therapeutics is 37.
Annual revenue of MiNA Therapeutics is $23.07M as on Dec 31, 2021.
Developer of small activating RNA therapeutics. It develops a new class of medicines that restore or boost normal gene function, impacting protein-modulated pathways in cells. The company focuses on genetic medicine applications and collaborates with pharmaceutical companies to expand its technology platform into other therapeutic areas. A systematic approach allows for rapid development of new medicines, moving from concept to clinical trials within a short timeframe. One RNA medicine has completed clinical trials.
MiNA Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
MiNA Therapeutics offers RNAa Therapeutics and Pipeline Programs.
MiNA Therapeutics has 4 investors. Key investors include Lilly, Boehringer Ingelheim, Nxera Pharma, and aMoon.